Cargando…
The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) affects 43,000 women worldwide every year and has a five-year survival rate of 30%. Mainstay treatment is extensive surgery and chemotherapy. Outcomes could be improved by molecular profiling. We conducted a review of the literature to identify relevant publications o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408825/ https://www.ncbi.nlm.nih.gov/pubmed/32679669 http://dx.doi.org/10.3390/jcm9072239 |
_version_ | 1783567921865293824 |
---|---|
author | Dion, Ludivine Carton, Isis Jaillard, Sylvie Nyangoh Timoh, Krystel Henno, Sébastien Sardain, Hugo Foucher, Fabrice Levêque, Jean de la Motte Rouge, Thibault Brousse, Susie Lavoué, Vincent |
author_facet | Dion, Ludivine Carton, Isis Jaillard, Sylvie Nyangoh Timoh, Krystel Henno, Sébastien Sardain, Hugo Foucher, Fabrice Levêque, Jean de la Motte Rouge, Thibault Brousse, Susie Lavoué, Vincent |
author_sort | Dion, Ludivine |
collection | PubMed |
description | Epithelial ovarian cancer (EOC) affects 43,000 women worldwide every year and has a five-year survival rate of 30%. Mainstay treatment is extensive surgery and chemotherapy. Outcomes could be improved by molecular profiling. We conducted a review of the literature to identify relevant publications on molecular and genetic alterations in EOC. Approximately 15% of all EOCs are due to BRCA1 or BRCA2 mutations. Four histologic subtypes characterized by different mutations have been described: serous, endometrioid, mucinous, and clear-cell. Between 20–30% of high-grade serous EOCs have a BRCA mutation. Tumors with BRCA mutations are unable to repair double-strand DNA breaks, making them more sensitive to platinum-based chemotherapy and to PolyAdenosine Diphosphate-Ribose Polymerase (PARP) inhibitors. Olaparib is a PARP inhibitor with proven efficacy in BRCA-mutated ovarian cancer, but its effectiveness remains to be demonstrated in tumors with a BRCAness (breast cancer) profile (i.e., also including sporadic tumors in patients with deficient DNA repair genes). A universally accepted molecular definition of BRCAness is required to identify optimal theranostic strategies involving PARP inhibitors. Gene expression analyses have led to the identification of four subgroups of high-grade serous EOC: mesenchymal, proliferative, differentiated, and immunoreactive. These subtypes are not mutually exclusive but are correlated with prognosis. They are not yet used in routine clinical practice. A greater understanding of EOC subtypes could improve patient management. |
format | Online Article Text |
id | pubmed-7408825 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74088252020-08-13 The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer Dion, Ludivine Carton, Isis Jaillard, Sylvie Nyangoh Timoh, Krystel Henno, Sébastien Sardain, Hugo Foucher, Fabrice Levêque, Jean de la Motte Rouge, Thibault Brousse, Susie Lavoué, Vincent J Clin Med Review Epithelial ovarian cancer (EOC) affects 43,000 women worldwide every year and has a five-year survival rate of 30%. Mainstay treatment is extensive surgery and chemotherapy. Outcomes could be improved by molecular profiling. We conducted a review of the literature to identify relevant publications on molecular and genetic alterations in EOC. Approximately 15% of all EOCs are due to BRCA1 or BRCA2 mutations. Four histologic subtypes characterized by different mutations have been described: serous, endometrioid, mucinous, and clear-cell. Between 20–30% of high-grade serous EOCs have a BRCA mutation. Tumors with BRCA mutations are unable to repair double-strand DNA breaks, making them more sensitive to platinum-based chemotherapy and to PolyAdenosine Diphosphate-Ribose Polymerase (PARP) inhibitors. Olaparib is a PARP inhibitor with proven efficacy in BRCA-mutated ovarian cancer, but its effectiveness remains to be demonstrated in tumors with a BRCAness (breast cancer) profile (i.e., also including sporadic tumors in patients with deficient DNA repair genes). A universally accepted molecular definition of BRCAness is required to identify optimal theranostic strategies involving PARP inhibitors. Gene expression analyses have led to the identification of four subgroups of high-grade serous EOC: mesenchymal, proliferative, differentiated, and immunoreactive. These subtypes are not mutually exclusive but are correlated with prognosis. They are not yet used in routine clinical practice. A greater understanding of EOC subtypes could improve patient management. MDPI 2020-07-15 /pmc/articles/PMC7408825/ /pubmed/32679669 http://dx.doi.org/10.3390/jcm9072239 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Dion, Ludivine Carton, Isis Jaillard, Sylvie Nyangoh Timoh, Krystel Henno, Sébastien Sardain, Hugo Foucher, Fabrice Levêque, Jean de la Motte Rouge, Thibault Brousse, Susie Lavoué, Vincent The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer |
title | The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer |
title_full | The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer |
title_fullStr | The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer |
title_full_unstemmed | The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer |
title_short | The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer |
title_sort | landscape and therapeutic implications of molecular profiles in epithelial ovarian cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408825/ https://www.ncbi.nlm.nih.gov/pubmed/32679669 http://dx.doi.org/10.3390/jcm9072239 |
work_keys_str_mv | AT dionludivine thelandscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT cartonisis thelandscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT jaillardsylvie thelandscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT nyangohtimohkrystel thelandscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT hennosebastien thelandscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT sardainhugo thelandscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT foucherfabrice thelandscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT levequejean thelandscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT delamotterougethibault thelandscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT broussesusie thelandscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT lavouevincent thelandscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT dionludivine landscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT cartonisis landscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT jaillardsylvie landscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT nyangohtimohkrystel landscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT hennosebastien landscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT sardainhugo landscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT foucherfabrice landscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT levequejean landscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT delamotterougethibault landscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT broussesusie landscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer AT lavouevincent landscapeandtherapeuticimplicationsofmolecularprofilesinepithelialovariancancer |